reports
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise Proceeds to Support Inorganic Growth and General Working Capital Purposes TAMPA, Fla., March 04, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, announced today that it has received $1,053,605 from the exercise of 75,257,511 previously issued warrants. The funds received will be used to fund the Company’s transition to a hybrid-biopharmaceutical company through strategic acquisitions, as well as for general working capital purposes. In connection with the exercise, the holders received f...
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precis...
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc. Targets one of Healthcare’s Largest Multi-Billion Dollar Markets: Cardiac Electrophysiology TAMPA, Fla., Jan. 11, 2022 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company, today announced that it has entered into a letter of intent for the acquisition of Catheter Precision, Inc. Catheter Precision is a medical device company focused on one of healthcare’s largest multi-billion dollar markets: Cardiac Electrophysiology. Catheter Precision has developed two cost-effective, user frie...
H-CYTE Names Michael Yurkowsky Chief Executive Officer
H-CYTE Names Michael Yurkowsky Chief Executive Officer TAMPA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced that it has named Michael Yurkowsky as its Chief Executive Officer effective immediately. Michael Yurkowsky brings more than 25 years of experience in financial services to H-CYTE. He currently has served on the Company’s board of directors since 2019. He also serves as President and Chairman of Deverra Therapeutics, a clinical stage biotech developing allogeneic cel...
H-CYTE Combines Clinical Outcomes and Scientific Development to Launch...
H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health Name change reflects investment in, and emphasis on, data-driven, patient-centric care relating to the company’s innovative PRP-PBMC treatment for chronic lung disorders. CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company dedicated to developing and delivering new treatments for patients with chronic respiratory and pulmonary disorders, today announced the launch of its newly-named ‘Centers for Respiratory Health’. Effec...
H-CYTE Announces Publication of Additional Data that Further Supports ...
H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health Study Successfully Met Goal of Statistically Significant Improvement in Pulmonary Function at 3 Months Post-Treatment TAMPA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of new data supporting the safety and efficacy of its innovative autologous treatment in helping improve overall lung health. Pu...
H-CYTE Announces Publication of Positive Real-World Data Relating to t...
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health Statistically Significant Improvement in Pulmonary Function at Both 3 Months and 12 Months Post Treatment TAMPA, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company focused on the field of regenerative medicine, today announced the publication of its clinical observational study titled, “Longitudinal Assessment of FEV1 Change Following Autologous Cellular Therapy.” The study, published ...
Robert Greif named Chief Executive Officer of H-CYTE
Robert Greif named Chief Executive Officer of H-CYTE Company to develop a platform of next-generation cellular therapeutics TAMPA, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a developer of regenerative cellular therapeutics, announced today that Robert Greif has been named the company’s new chief executive officer. “Robert brings decades of pharmaceutical experience to H-CYTE, having successfully taken more than a dozen products from discovery to commercialization,” said Ray Monteleone, H-CYTE board member and chair of the CEO search committee. “We believe h...
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, Sept...
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020 TAMPA, Fla., Sept. 03, 2020 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company that develops and implements innovative treatment options in regenerative medicine to help manage chronic obstructive pulmonary disease (COPD) and other debilitating lung diseases, announced today that it has extended the expiration time of its rights offering to 5:00 PM Eastern Time on September 11, 2020 to provide additional time to accommodate shareholder orders and delays in processing. Under the ...
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, Sept...
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020 TAMPA, Fla., Sept. 02, 2020 (GLOBE NEWSWIRE) -- H-CYTE, Inc. (OTCQB: HCYT), a medical biosciences company that develops and implements innovative treatment options in regenerative medicine to help manage chronic obstructive pulmonary disease (COPD) and other debilitating lung diseases, announced today that H-CYTE has extended the expiration time of its rights offering to 5:00 PM Eastern Time on September 11, 2020 to provide additional time to accommodate shareholder orders and delays in processing. Under ...
H-CYTE Issues Letter to Shareholders
H-CYTE Issues Letter to Shareholders TAMPA, Fla., Jan. 21, 2020 (GLOBE NEWSWIRE) -- (OTCQB: HCYT) the owner and operator of innovative medical technology products and services including LungCYTE and , today issued the following letter to shareholders from its CEO Bill Horne. Dear Fellow Shareholders, We have made significant progress toward our dramatic strategic goals due to the support of our gracious and accomplished investors. They share our vision for the future of the state of medicine. They understand that focusing on serving our patients is the best way possible to ...
H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Ge...
H-CYTE Raises $6 Million to Accelerate FDA Approval Process of Next Generation Cellular Therapy for COPD Broadcast.com Co-Founder Todd Wagner Among New Investors in Company Behind Lung Health Institute TAMPA, Fla., Nov. 18, 2019 (GLOBE NEWSWIRE) -- (OTCQB: HCYT) the owner and operator of innovative medical technology products and services including LungCYTE and , announces it has raised $6 million in new funding. The investment is in the form of preferred stock which may be converted into shares of common stock at a fixed price in excess of the current market, at approximately $.41 p...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Atta Behfar...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Atta Behfar to its Board of Directors TAMPA, Fla., July 30, 2019 (GLOBE NEWSWIRE) -- (OTCQB: HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including , today announced it has appointed to its Board of Directors. Atta Behfar, M.D., Ph.D., is a transplant cardiologist and Associate Professor of Medicine at . He leads translational and CGMP manufacturing activities in the Center for Regenerative Medicine and is Director of the Van Cleve Cardiac Regenerative Medicine...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Andre Terzi...
H-CYTE Bolsters Board of Directors With Appointment of Dr. Andre Terzic to Board of Directors TAMPA, Fla., July 29, 2019 (GLOBE NEWSWIRE) -- Inc. (OTCQB: HCYT) (“H-CYTE” or the “Company”), the owner and operator of innovative medical technology products and services including , today announced it has appointed , to its Board of Directors. Dr. Andre Terzic is the Michael & Mary Sue Shannon Director, , Marriott Family Professor of Cardiovascular Diseases Research and Professor of Medicine and Pharmacology. A pioneer in cardiovascular regenerative medicine, Dr. Terzic has dedicated his car...
H-CYTE Comments on Recent Promotional Activity
H-CYTE Comments on Recent Promotional Activity TAMPA, Fla., July 17, 2019 (GLOBE NEWSWIRE) -- H-CYTE, INC. (OTCQB: HCYT), wishes to make, at the request of the OTC Markets Group Inc., the following release regarding certain market activity surrounding the Company's common shares. On July 15, 2019, the Company was notified by the OTC Markets about certain promotional activities in relation to the Common Shares, including certain promotional newsletter emails dated July 12, 2019 and July 15, 2019, distributed by Penny Stock Prophet, Secret Stock Promoter and OTC Tip Reporter. At no time ha...
Medovex Corporation Announces Name Change to H-CYTE and New Ticker Sym...
Medovex Corporation Announces Name Change to H-CYTE and New Ticker Symbol Company’s Shares to Trade Under Symbol “HCYT” at Opening of Trading on July 15, 2019 TAMPA, Fla., July 12, 2019 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: MDVX), today announced that FINRA has approved the effectiveness of a change in the company’s name from “Medovex Corp.” to “H-CYTE, Inc.” as well as a change in the Company’s trading symbol from “MDVX” to the new trading symbol “HCYT”. The change will become effective on the opening of trading as of Monday, July 15, 2019. In addition, a new CUSIP number has bee...
Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE
Medovex Corporation Updates Name Change and Full Rebranding to H-CYTE TAMPA, Fla., July 01, 2019 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: MDVX), today updated investors on its name change and rebranding to H-CYTE. The announcement underscores the Company's broader commitment focusing on delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients, as well as bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases. In addition to the name and anticipat...
Medovex’s Transition to H-CYTE Underscores Biotechnology Focus
Medovex’s Transition to H-CYTE Underscores Biotechnology Focus Announces Long-Term Agreement to Launch a Promising New Cellular Treatment for COPD ALPHARETTA, Ga., June 24, 2019 (GLOBE NEWSWIRE) -- Medovex Corp. (OTCQB: Symbol MDVX) ("Medovex" or the "Company"), is transitioning to its new name H-CYTE Inc. (“H-CYTE”) to underscore its focus of delivering regenerative anti-inflammatory solutions to treat the unmet needs of patients. Within its portfolio, the Company announced today H-CYTE will enhance its existing cytotherapy product line, developing a disruptive technology for chronic ...
Medovex Corporation Announces Recent Management Appointments
Medovex Corporation Announces Recent Management Appointments Highly Experienced Team Responsible for Building a Previous $250M Plus Revenue Health Care Enterprise Reunited Under CEO Bill Horne ALPHARETTA, Ga., April 29, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”), the owner and operator of innovative medical technology products and services including Lung Health Institute and the DenerveX® System, today announced a series of new management appointments bolstering its management team following the recent appointment of Bill Horne as Chief Execu...
Medovex Corporation Receives an Additional $1.25 Million Under Existin...
Medovex Corporation Receives an Additional $1.25 Million Under Existing Securities Purchase Agreement Increases Maximum Offering Size from $6M to $8M ALPHARETTA, Ga., March 18, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”) today announced that on March 11, 2019, the Company entered into a securities purchase agreement with eight purchasers pursuant to which the purchasers invested in the Company an aggregate amount of $1,250,000. Pursuant to the agreement, the Company increased the maximum offering size from $6,000,000 to $8,000,000 The Company...
Medovex Corporation Announces Name Change and Full Rebranding to Blue ...
Medovex Corporation Announces Name Change and Full Rebranding to Blue Zone Health New Company Identity Expands Focus to Deliver Innovative Health Care Solutions Around the World ALPHARETTA, Ga., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Medovex Corporation (OTCQB: MDVX) (“Medovex” or the “Company”) today announced it is now Blue Zone Health. The announcement signals the company's broader commitment to bringing new health care solutions to patients domestically and internationally with a focus on improving quality of life, especially for those with chronic diseases. Blue Zone Health adopts ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.